Investor Relations
About Vivani
Vivani Medical is an emerging biopharmaceutical company developing a pipeline of miniature, long-term, subdermal, drug implants with its proprietary NanoPortal™ technology.
Vivani’s lead assets, NPM-115 and NPM-119, are miniature, six-month, GLP-1 (exenatide) implants under development for chronic weight management obesity and type 2 diabetes, respectively. NPM-115 and NPM-119 are designed to optimize GLP-1 therapy by addressing two main challenges in achieving the full potential benefits of this therapy, medication non-adherence and tolerability.
As a result of positive preclinical weight loss data comparing NPM-115 to Ozempic/Wegovy and the transformational change in the obesity market, Vivani has decided to prioritize development of its obesity portfolio moving forward which also includes NPM-139 (semaglutide implant) with the potential for once-yearly dosing.
Vivani continues to proceed towards initiating LIBERATE-1, a First-in-Human (FIH) study assessing NPM-119’s safety and pharmacokinetic profile in type 2 diabetes patients. In addition to an active control arm with Bydureon BCise, LIBERATE-1 will also assess NPM-119’s effect on both glycemic control and weight.
NanoPortal™ has broad potential application across a range of molecule types including peptide therapeutics.